Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 20/9/2020
SIETES contiene 93097 citas

 1 a 20 de 106 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Moore TJ, Hanzhe Z, Anderson G, Alexander C. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016. JAMA Intern Med 2018:24 de septiembre. [Ref.ID 102831]
3.Tiene citas relacionadas Cita con resumen
Davis C, Lexchin J, Jefferson T, Gotzsche P, McKee M. "Adaptive pathways” to drug authorisation: adapting to industry?. BMJ 2016;354:i4437. [Ref.ID 100602]
4. Cita con resumen
Jones ChW, Handler L, Crowell KE, Keil LG, Weaver MA, Platts-Mills TF. Non-publication of large randomized clinical trials: cross sectional analysis. BMJ 2013;347:14. [Ref.ID 96709]
5.Tiene citas relacionadas Cita con resumen
Califf RM, McCall J, Harrington RA. Assessing research results in the medical literature: trust but verify. JAMA Intern Med 2013;173:1053-5. [Ref.ID 95719]
6. Cita con resumen
Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ 2013;346:15. [Ref.ID 95533]
7. Cita con resumen
8. Cita con resumen
Duijnhoven RG, Straus SMJM, Raine JM, de Boer A, Hoes AW, De Bruin ML. Number of patients studied prior to approval of new medicines: database analysis. PLOS Medicine 2013;10:1. [Ref.ID 95146]
9.Tiene citas relacionadas Cita con resumen
Ioannidis JPA. Mega-trials for blockbusters. JAMA 2013;309:239-40. [Ref.ID 94781]
10.Enlace a cita original
Dzingina M, Stegenga H, Heath M, Rogers G, Kleijnen J, Armstrong N, Howdle PD, on behalf of the Guideline Development Group. Assessment and referral after emergency treatment of a suspected anaphylactic episode: summary of NICE guidance. BMJ 2011;343:1270-1. [Ref.ID 91960]
11. Cita con resumen
Siontis KCM, Evangelou E, Ioannidis JPA. Magnitude of effects in clinical trials published in high-impact general medical journals. Int J Epidemiol 2011;40:1280-91. [Ref.ID 91577]
12. Cita con resumen
Araya Alpízar C, Galindo Villardon MP. Tamaño de la muestra en investigación clínica. Med Clin (Barc) 2009;133:26-30. [Ref.ID 86075]
13.Tiene citas relacionadas Cita con resumen
Shen L, Kendall DM, Buse JB, Burns C, Taylor KL. Exenatide for type 2 diabetes. Authors' reply. Lancet 2009;373:122-3. [Ref.ID 85004]
14.Tiene citas relacionadas Cita con resumen
Garattini S, Bertele V, Floriani I, Torri V. Exenatide for type 2 diabetes. Lancet 2009;373:122. [Ref.ID 85003]
15. Cita con resumen
Chan-AW, Hróbjartsson A, Jorgensen KJ, Gotzsche PC, Altman DG. Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. BMJ 2008;337:1404-7. [Ref.ID 84756]
16.Tiene citas relacionadas Cita con resumen
Garattini S, Bertele V. Non-inferiority trials are unethical because they disregard patients' interests. Lancet 2007;370:1875-7. [Ref.ID 81662]
17. Cita con resumen
Schulz KF, Grimes DA. Sample size calculations in randomised trials: mandatory and mystical. Lancet 2005;365:1348-53. [Ref.ID 73380]
18. Cita con resumen
Chan AW, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet 2005;365:1159-62. [Ref.ID 73234]
19. Cita con resumen
Colhoun HM, McKeigue PM, Smith GD. Problems of reporting genetic associations with complex outcomes. Lancet 2003;361:865-72. [Ref.ID 65299]
20. Cita con resumen
Horrobin DF. Are large clinical trials in rapidly lethal diseases usually unethical?. Lancet 2003;361:695-7. [Ref.ID 65125]
Seleccionar todas
 1 a 20 de 106 siguiente >>